Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Degenerative Disc Disease With Allogenic Mesenchymal Stem Cells (MSV)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Degenerative disease of one or two lumbar discs with predominant back pain after conservative treatment (physical and medical) for over 6 months.~* Fibrous ring capable of holding the cell implantation, demonstrated by Magnetic resonance imaging (MRI) image (stages 2, 3 and 4 of Adams).~* Decrease of disc height of more than 20% (radiographic measurement in side image).~* Absence of spinal infection.~* Haematological and biochemical analysis wit no significant alterations that contraindicates intervention.~* The patient is able to understand the nature of the study.~* Informed written consent of the patient.~Exclusion Criteria:~* Age over 75 or under 18 or legally dependent~* Allergy to gentamicin, or to bovine, cattle or horse serum.~* Congenital or acquired diseases leading to spine deformations that may upset cell application.~* Spinal segmental instability, spinal canal stenosis, isthmus pathology and other conditions that may compromise the study~* Modic III changes on MRI images (31).~* Overweight with body mass index (mass in Kg/size in m2) greater than 35 (obesity grade II).~* Pregnancy or breast-feeding~* Neoplasia~* Immunosuppression~* Participation in another clinical trial or treatment with another investigational product within 30 days prior to inclusion in the study.~* Other conditions that may, according to medical criteria, discourage participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Allogenic Mesenchymal Stromal Cells (Type: EXPERIMENTAL): Mesenchymal stem cells (MSC) prepared from bone marrow from healthy donor expanded ex vivo for 3-4 weeks. Intradiscal injection of 25 millions MSC in 2 ml of saline
- Mepivacaine (Type: ACTIVE_COMPARATOR): Infiltration of paravertebral musculature close to the affected disc(s) with 2 ml of 1% Mepivacaine

Based on this trial design, predict the completion outcome and termination type (if applicable).